Divi’s Laboratories announced a consolidated total income of ₹2,860 crores for Q2 FY26, compared to ₹2,444 crores in the corresponding quarter of the previous year. Profit before tax (PBT) for the quarter was ₹912 crores, up from ₹722 crores. The company reported a profit after tax (PAT) of ₹689 crores compared to ₹510 crores. Forex gain for the quarter stood at ₹63 crores.
Financial Performance in Q2 FY26
Divi’s Laboratories reported a consolidated total income of ₹2,860 crores for the quarter ended September 30, 2025, marking an increase from the ₹2,444 crores recorded in the same quarter of the previous year. The company’s profit before tax (PBT) reached ₹912 crores, surpassing the ₹722 crores from the corresponding period. Profit after tax (PAT) amounted to ₹689 Crores, exceeding the ₹510 crores reported previously.
Half-Year Performance (H1 FY26)
For the half year ended September 30, 2025, Divi’s Laboratories reported a consolidated total income of ₹5389 crores, up from ₹4640 crores in the previous year. The profit before tax (PBT) was reported as ₹1645 crores against ₹1326 crores from the previous year. The company’s profit after tax (PAT) stood at ₹1234 crores compared to ₹940 crores for the corresponding half year. The current half-year benefited from a forex gain of ₹102 crores, compared to a gain of ₹28 crores in the corresponding period.
Standalone Financial Performance
On a standalone basis, Divi’s Laboratories reported a total income of ₹2806 crores for the quarter, with a PBT of ₹920 crores and a PAT of ₹696 crores. Forex gain was ₹64 crores. For the half year, the total income was ₹5282 crores, with a PBT of ₹1667 crores and a PAT of ₹1253 crores. Forex gain for the half year was ₹103 crores.
Senior Management Change
Mr. Nimmagadda Venkata Anirudh has been appointed as President (Nutraceuticals) and Senior Management Personnel, effective from November 07, 2025. He will lead the nutraceutical business and report directly to the Chief Executive Officer.
Source: BSE
